NCT04571489 - A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

December 1, 2021

Study Completion Date

December 1, 2023

Conditions

Pancreatic Cancer

Interventions

DRUG

Gimatecan

Patients will receive gimatecan orally at 0.8mg/m2 on day 1-5 every 4 weeks.

DRUG

tegafur, gimeracil and oteracil potassium

Patients will receive tegafur, gimeracil and oteracil potassium orally at 40 or 60mg twice daily on days 1 to 14 every 3 weeks.

DRUG

gemcitabine

Patients will receive gemcitabine IV at 1000mg/m2 on days 1、8 every 3 weeks.

Trial Locations (1)

Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai